Publications by authors named "K Thoms"
Background: Up to now, the optimal duration of immune checkpoint inhibitors (ICI) has not been evaluated in prospective studies. However, current clinical practice requires decisions to be made regarding the duration of ICI in complete responders.
Material And Methods: A survey was sent to 80 DeCOG skin cancer centers to assess how decisions are made on treatment duration of ICI in melanoma after having reached complete response, and staging intervals after ICI discontinuation.
Background: Immune checkpoint inhibitor (ICI)-induced myocarditis is a rare immune-related adverse event (irAE) with a fatality rate of 40%-46%. However, irMyocarditis can be asymptomatic. Thus, improved monitoring, detection and therapy are needed.
View Article and Find Full Text PDFArticle Synopsis
- - The treatment options for metastatic uveal melanoma (UM) are still limited and the overall prognosis is poor, despite recent advancements; immune checkpoint blockade (ICB) is a common treatment but can cause severe adverse effects.
- - A study involving 194 patients analyzed the relationship between immune-related adverse events (irAE) and survival outcomes, finding that those with severe irAE had better overall survival compared to those without or with mild irAE.
- - The results suggest that certain types of irAE, like irColitis and irHepatitis, may be linked to longer survival, indicating that a lower tolerance to tumor antigens might correlate with a lower tolerance to self-antigens.
Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown.
View Article and Find Full Text PDFIntroduction: Multi-professional interdisciplinary tumor boards (ITB) are essential institutions to discuss all newly diagnosed, relapsed or complex cancer patients in a team of specialists to find an optimal cancer care plan for each individual patient with regard to national and international clinical practice guidelines, patient´s preference and comorbidities. In a high-volume cancer center, entity-specific ITBs take place at least once a week discussing a large number of patients. To a high level of expertise and dedication, this also requires an enormous amount of time for physicians, cancer specialists and administrative support colleagues, especially for radiologists, pathologists, medical oncologists and radiation oncologists, who must attend all cancer-specific boards according to certification requirements.
View Article and Find Full Text PDF